Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $12.75 and last traded at $12.96, with a volume of 437384 shares. The stock had previously closed at $13.07.
SNDX has been the topic of a number of analyst reports. UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a "buy" rating and a $37.00 price objective on the stock. Citigroup boosted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, November 19th. Stifel Nicolaus raised their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. The Goldman Sachs Group boosted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.90.
Check Out Our Latest Report on SNDX
The stock's 50 day simple moving average is $16.90 and its two-hundred day simple moving average is $19.12. The firm has a market cap of $1.10 billion, a P/E ratio of -3.54 and a beta of 0.86.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the prior year, the company posted ($0.73) EPS. Equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $27,000. Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter valued at about $30,000. nVerses Capital LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter valued at about $33,000. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after buying an additional 541 shares during the last quarter.
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.